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1 
Abstract—Mobile applications are being used to perform a wide 
variety of tasks in day-to-day life ranging from checking email, to 
controlling your home heating. Application developers have 
recognized the potential to transform a smart device into a medical 
device, by using a mobile medical application i.e. a mobile phone or 
a tablet. When initially conceived these mobile medical applications 
performed basic functions e.g. BMI calculator, accessing reference 
material etc.; however, increasing complexity offers clinicians and 
patients a range of functionality. As this complexity and functionality 
increases, so too does the potential risk associated with using such an 
application. Examples include any applications that provide the 
ability to inflate and deflate blood pressure cuffs, as well as 
applications that use patient-specific parameters and calculate dosage 
or create a dosage, plan for radiation therapy. If an unapproved 
mobile medical application is marketed by a medical device 
organization, then they face significant penalties such as receiving an 
FDA warning letter to cease the prohibited activity, fines and 
possibly face criminal conviction. 
Regulatory bodies have finalized guidance intended for mobile 
application developers to establish if their applications are subject to 
regulatory scrutiny. However, regulatory controls appear 
contradictory with the approaches taken by mobile application 
developers who generally work with short development cycles and 
very little documentation and as such, there is the potential to stifle 
further improvements due to these regulations. The research 
presented as part of this paper details how by adopting development 
techniques such as agile software development, mobile medical 
application developers can meet regulatory requirements whilst still 
fostering innovation. 
 
Keywords—Medical, Mobile, Applications, Software 
Engineering, FDA, Standards, Regulations, Agile.  
I. INTRODUCTION 
N early 2009, Apple first demonstrated how mobile devices 
could be used in connection with medical devices. At their 
annual World Wide Developer Conference they connected 
blood pressure monitors and blood glucose meters to an 
IPhone via Bluetooth and cable [1]. In 2014, a report was 
released which stated that there are over 100,000 Mobile 
Medical Applications (MMA) available on the two major 
mobile platforms, IOS and Android. The same report stated 
that this market was worth $4 billion and this could potentially 
rise to as much $26 billion by 2017 [2]. Evidence of this 
growing popularity can be seen by the major platform 
providers who are not simply supporting these applications 
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(apps), but they are now integrating these apps directly with 
their operating systems e.g. Google Fit, Health from Apple 
and Microsoft Health.  
MMAs typically meet the definition of being mHealth i.e. 
“the use of wireless communication to support efficiency in 
public health and clinical practice” [3]. Furthermore, by their 
very nature, MMAs are deemed as medical device software. 
Medical device software can be: 
• Standalone software; 
• Embedded software; 
• Software, which transforms a device into a regulated 
medical device. 
To accompany this, research has shown that not only are 
these apps being developed at a high rate, but also clinicians 
worldwide are adopting them. In 2015, approximately 500 
million people used mobile medical applications [4]-[5].  
With MMAs becoming increasingly prevalent, regulatory 
bodies determined that regulations or guidance was needed for 
app developers to establish if they required regulatory 
approval prior to being marketed for use [6].  Within the 
United States (US), the Food and Drug Administration (FDA) 
regulate medical devices and within the European Union (EU), 
medical device regulations are created by the European 
Council and enforced by notified bodies within each member 
state. 
The first step in regulating MMAs was the release of the 
FDA Final Rule on Medical Device Data Systems (MDDS). 
This rule aimed to provide clear guidance as to when software 
or devices could be deemed as Class I devices and would 
require the lowest level regulatory scrutiny. However, 
confusion remained amongst apps developers if their app did 
not meet the definition of being a MDDS or a MMA. To 
provide further guidance, the FDA released its draft guidance 
for mobile medical application developers in 2011 with the 
final version of this guidance document being released in 
2015. The aim of this document was to remove ambiguity 
surrounding the regulation of MMA. 
In the past, app development organizations who have 
attempted to innovate and revolutionize the healthcare 
industry through MMAs, have been stifled by regulations 
leading to a reluctance to other manufacturers to enter the 
market [7]. One of the key advantages to mobile applications 
is that development costs are typically low as the application 
is not as complete as a fully-fledged software application [8]. 
Mobile application manufacturers typically do not produce 
comprehensive documentation and do not develop their apps 
in accordance with any defined software development 
technique. Whilst this approach may be acceptable when 
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developing traditional mobile applications, it is not acceptable 
for developing MMAs, as regulatory bodies require 
comprehensive documentation as evidence of the safety and 
efficacy of the application. 
Agile software development techniques have been adopted 
by traditional app development organizations. Agile methods 
offer reduced development costs, improved time to market and 
a shorter development lifecycle [9].  However, research has 
revealed a slow rate of adoption of agile methods by 
organizations developing software for use in the medical 
domain [10]. Where agile methods have been adopted for 
developing software for use in the medical domain, the 
organizations involved have reported significant benefits [11], 
[12].  
The remainder of this paper is structured as follows: section 
2 provides background to the approach taken by regulatory 
bodies with regards the use of software in a healthcare 
environment; section 3 explains further what a mobile medical 
application is in terms of how is its viewed by regulatory 
bodies; section 4 discusses how software development 
techniques such as agile software development can be used to 
achieve regulatory deliverables whilst fostering innovation 
when developing MMAs and section 5 provides the 
conclusions derived from this research. 
II. BACKGROUND 
A. Regulations 
In 1981, the FDA began to investigate the use of software in 
healthcare. Initially, the FDA classified medical device 
software based upon its Draft Software Policy published in 
1987 and revised in 1989 [13]. However, the FDA recognised 
that as the rate of computer and software-based products was 
growing at an exponential rate, it was not practical to adopt a 
single “software” policy, which would cover all computer and 
software based products. Consequently, the draft software 
policy was withdrawn in January 2005 [14]. As a result, the 
FDA does not specifically regulate software; rather it regulates 
devices used in healthcare, which meet the definition of being 
a medical device. The FDA definition of what constitutes a 
medical device is outlined in section 201(h) of the Federal 
Food Drug & Cosmetic (FD&C) Act [15].  
"an instrument, apparatus, implement, machine, 
contrivance, implant, in vitro reagent, or other similar or 
related article, including a component part, or accessory 
which is: 
• recognized in the official National Formulary, or the 
United States Pharmacopoeia, or any supplement to 
them, 
• intended for use in the diagnosis of disease or other 
conditions, or in the cure, mitigation, treatment, or 
prevention of disease, in man or other animals, or 
• intended to affect the structure or any function of the 
body of man or other animals, and which does not 
achieve its primary intended purposes through 
chemical action within or on the body of man or 
other animals and which is not dependent upon 
being metabolized for the achievement of any of its 
primary intended purposes." 
It can be seen from the definition provided that if software 
performs any of the functions outlined in the definition of a 
medical device, then it becomes subject to scrutiny by the 
FDA. 
1) Safety Classification 
All medical devices marketed for use within the US must 
receive a safety classification. This classification is 
determined based upon the potential risk a medical device 
poses on patients, clinicians or third parties. The three 
classifications are, Class I Low Risk, Class II Medium Risk 
and Class III High Risk. All medical devices initially receive a 
Class III safety classification unless they meet the definition of 
being in a device category with a lower classification or until 
they are reclassified by the FDA.    
2) 21 CFR 820 Quality Systems Regulations  
All medical devices marketed for use within the US 
regardless of device safety classification, must provide 
evidence of adoption of a Quality Management System 
(QMS), such as in accordance with 21 CFR 820 Quality 
Systems Regulations (QSR) [16] and the FDA Design Control 
Guidance for Medical Device Manufacturers [17]. Of note 
within the QSR is Subpart C – Design Controls, which 
provides information as to which processes must be adhered to 
when developing regulatory compliant software. These 
include: 
• Design & Development Planning (Specifications); 
• Design Output (Coding); 
• Design Review; 
• Design Verification (Was the Product Built Right?); 
• Design Validation (Was the Right Product Built?). 
The primary objective of the QSR is to ensure the safe and 
reliable performance of a medical device. A device is deemed 
safe if it does not cause harm to a patient, clinician or third 
party and it is deemed reliable if it performs the desired 
function each and every time it is used.  
3)  21 CFR 880 Medical Devices; Medical Device Data 
Systems Final Rule 
Prior to April 16th 2011, devices that now meet the current 
definition of being a MDDS were classified as either a Class 
III device, or assumed the safety classification of the parent 
medical device to which they were connected, although the 
FDA had been operating under their discretionary enforcement 
policy and therefore was not enforcing the Class III 
requirements on all MDDS.  However, on April 16th 2011, a 
FDA rule became effective which classified a MDDS device 
as Class I, 510 (k) exempt - medical device [14]. This ruling 
came three years after the proposed ruling was issued on 
February 8th 2008. This final classification modifies FDA 21 
C.F.R § 880.6310 and describes a MDDS as being: 
 “software, electronic, or electrical hardware such as 
a physical communications medium (including wireless 
  
hardware), modems, interfaces and communications 
protocol” 
The FDA provided the following definition of what 
constitutes a MDDS: 
“A device that is intended to provide one or more of 
the following uses, without controlling or altering the 
functions or parameters of any connected medical 
devices: 
(i) The electronic transfer of medical device data; 
(ii) The electronic storage of medical device data; 
(iii) The electronic conversion of medical device data 
from one format to another format in accordance 
with a pre-set specification; or 
(iv) The electronic display of medical device data.” 
There is however, an exception to this rule. If software 
exclusively performs one or more of the functions outlined in 
the definition of a MDDS and is used for active patient 
monitoring, then it cannot be considered a MDDS and must be 
considered an accessory or medical device in its own right. 
B. Standards 
In November 1997, the FDA signed into law the 
Modernization act, known as the Food and Drug 
Administration Modernization Act (FDAMA) [18]. A key 
element of FDAMA is the advocating of the use of standards 
in the design review process. To support the FDAMA, the 
FDA published in the Federal Register, a list of standards to 
which medical device manufacturers could declare 
conformity. A key objective of the FDAMA was to reduce the 
burden on both the FDA and medical device manufacturers by 
reducing the regulatory obstacle to entry to international and 
domestic medical device markets. When the FDAMA was 
signed into law, the Centre for Devices and Radiological 
Health (CDRH) established Standards Technology Groups 
(STG), one of which had a specific focus on software. A STG 
is responsible for software categorized as follows: 
• General process standards, which are technology 
independent; 
• General process standards, which are technology 
dependent; 
• Specific process implementations. 
A number of standards are included on the Federal Register 
list of standards; of most significance with regards to medical 
device software development is IEC 62304:2006 Medical 
Device – Software Life Cycle Processes [19]. Also of 
significance to medical device software and all types of 
medical device is ISO 14971:2012 Application of Risk 
Management to Medical Devices [20]. In the EU, ISO 
13485:2012 [21] Medical Devices – Quality Management 
Systems – Requirements for Regulatory Purposes is central to 
the development of regulatory compliant software. However, 
prior to March 2012, medical device companies wishing to 
market a medical device within the US were required to 
provide evidence of adherence to the FDA QSR regulations. 
Therefore, if a medical device manufacturer was developing a 
medical device for use in the EU and the US, they needed to 
conform to both of the quality management system guidelines. 
In March 2012, the FDA commenced a pilot program offering 
device manufacturers the option of submitting their quality 
system audits, which are compliant with ISO/IEC 13485:2012, 
to the FDA’s Centre for Devices and Radiological Health 
(CDRH) or Centre for Biologics Evaluation and Research 
(CBER) [22]. This is seen as a step forward in the FDA’s plan 
to create a partnership with Health Canada, which would 
result in a single audit program for both the US and Canada.  
1) IEC 62304:2006 Medical Device – Software Life Cycle 
Processes 
As medical devices are safety critical, manufacturers are 
recommended to follow current international standards during 
development. Adherence to these standards is not mandatory, 
but it is recommended in order to achieve regulatory approval. 
Adherence to the standards demonstrates the manufacturer’s 
ability to follow defined development procedures and to 
perform the required risk management activities [23]. If a 
manufacturer chooses not to adhere to these standards, they 
must provide a sufficient explanation as to why and they must 
demonstrate that the alternative method chosen is equally 
valid. Within the US, it is the responsibility of the FDA to 
ensure compliance with these standards. FDA auditors and 
Inspectors perform these compliance checks. 
IEC 62304:2006 is the current software development 
standard followed by medical device software developers. The 
current version of IEC 62304 was released in 2006. IEC 62304 
is derived from ISO/IEC 12207:1995 Software Lifecycle 
Processes [24],  AMD 1:2002 [25]  and 2:2004 [26]. ISO 
12207:1995 is not domain specific but it is seen as being 
comprehensive in its approach which is reflected in the 
number of standards that utilize the core principles of ISO 
12207:1995, AMD 1 and AMD 2 as their foundation such as 
ISO/IEC 15504-5:2006. IEC 62304 is domain specific and is 
tailored to suit the specific requirements of the medical device 
software development industry. IEC 62304 is a software 
development standard that provides end-to-end guidance in the 
development of the software component of a medical device. 
However, it hands off system activities such as Requirements 
Elicitation and Validation, to its aligned standards which 
include ISO 13485:2003 Medical Devices – Quality 
Management Systems [27], ISO 14971:2007 Medical Devices 
– Application of Risk [28]  and ISO/IEC 15288:2008 – 
Systems and Software engineering – System lifecycle 
processes [29]. IEC 62304 is a harmonized standard under the 
MDD [30] and is a FDA consensus standard [31].   
IEC 62304 makes provision for the application of risk to 
software. IEC 62304 applies a classification system to 
software components similar to that of ISO 14971 Clause 
4.4.5 and 6.1. The safety classification is as follows: 
• Class A – No injury or damage to health possible; 
• Class B – Non-serious injury is possible; 
• Class C – Death or serious injury is possible. 
The risk classification applied to an item of software is 
determined by the amount of potential risk the medical device 
places upon the patient, clinician or third party. With IEC 
62304, the overall software component assumes the safety 
  
classification of the software element that poses the most risk. 
However, IEC 62304 does make allowance for software 
components to be segregated into individual software elements 
with each element receiving its own safety classification.  
2) ISO 13485:2012 Medical Devices – Quality Management 
Systems – Requirements for Regulatory Purposes  
ISO 13485:2012 was published in 2012, which forms the 
basis for the development of a quality management system 
when developing medical device software. ISO 13485 is 
derived from ISO 9001; however, ISO 13485 is tailored to 
include elements specific to the development of medical 
devices. Additionally, ISO 9001 requires a device 
manufacturer to perform continuous improvement, while ISO 
13485 only requires a manufacturer to implement and 
maintain a quality management system. As previously 
discussed, the FDA now accepts quality management audits 
performed in accordance with ISO 13485. 
3) ISO 14971:2012 – Application of Risk Management to 
Medical Devices 
ISO 14971 was first released in 2000 with the second 
edition released in 2007 and the latest version released in 
2012. ISO 14971 is a FDA consensus standard. It specifies the 
procedures and activities for identifying hazards in medical 
devices and accessories to medical devices, including 
software. ISO 14971 provides guidelines to medical device 
manufacturers on the preparation of a plan to prepare for risk 
management activities. The plan should contain: 
• The scope of the plan; 
• A verification plan; 
• Allocation of responsibilities; 
• Requirements for review of risk management activities; 
• Requirements for collecting and reviewing production and 
post-production information; 
• Criteria for risk acceptability. 
ISO 14971 is not specific to the development of medical 
device software. As a result, it can be difficult to apply it to 
the development of medical device software. Consequently, 
IEC produced a Technical Report (TR) providing guidance to 
medical device manufacturers on applying ISO 14971. This 
guidance document is known as IEC/TR 80002-1:2009 – Part 
1: Guidance on the application of ISO 14971 to medical 
device software [32]. IEC/TR 80002-1:2009 follows the same 
structure as ISO 14971, making it easier to follow for those 
familiar with ISO 14971’s structure. 
III. MOBILE MEDICAL APPLICATIONS 
A. When is an App a Mobile Medical App? 
A mobile application is defined as standalone software that 
exists on a smart device such as a mobile phone or tablet [8]. 
Table I shows a number of key terms and definitions relevant 





KEY TERMS AND DEFINITIONS [8] 
Term Definition 
Native Software that comes pre-installed on a mobile 
device such as Google Fit. 
Downloadable Software that is not pre-installed on a device 
but can be downloaded and installed from 
another sources. 
Web-Based An application that is accessed via a mobile 
device however no installation or download 




An online portal which facilities the searching 
for, and downloading of downloadable mobile 
application e.g. App store or Google Play. 
Mobile Device 
OS 
The primary operating system, which resides 
on a mobile device e.g. IOS or Android. 
 
The FDA Mobile Medical Applications, Guidance for 
Industry and Food and Drug Administration Staff [33] defines 
a mobile medical application as: 
“a mobile medical application is a mobile app that 
meets the definition of a device in section 201(h) of the 
Federal Food, Drug, and Cosmetic Act; and either is 
intended: 
• To be used as an accessory to a regulated medical 
device; or 
• To transform a mobile platform into a regulated 
medical device.” 
The FDA recognized that the definition could cause 
confusion and as such, they went on further to explain that the 
intended use of the mobile application would determine 
whether or not it meets the definition of being a “device”.  For 
example, if a mobile application developer makes an app that 
turns on a mobile device’s flash for the purpose of a torch for 
general use, then this app is not defined as being a medical 
device. However, if the app developer through marketing and 
labeling intended the app for use by clinicians to assist with 
their daily tasks, then this application would meet the 
definition of being a “device”.   
In instances such as this, the labeling and marketing would 
establish the intended use, as the app could potentially be used 
within multiple domains. However, where apps have been 
developed with a clear medical focus but have not been 
labeled and marketed for medical use, then this app would still 
meet the definition of being a device as no ambiguity 
surrounds the intended use. For example, if an app developer 
created an app that helped analyze ECG results then regardless 
of labeling, this app would be subject to regulatory controls. 
Prior to the FDA releasing its draft guidance on mobile 
medical applications, app developers were avoiding any form 
of regulatory control by labeling their apps as lifestyle apps. 
This loophole has now been closed. 
B. Who is a Mobile Medical Application Manufacturer? 
In other domains it may be clear who the developer of a 
specific software product is i.e. the software development 
organization producing a software package would be deemed 
the manufacturer. However, in line with other medical device 
regulations, confusion initially arose as to who was defined as 
being a mobile medical application manufacturer. In the 
production of other forms of medical devices such as infusion 
  
pumps and CT scanners, FDA 21 CFR Parts 803 [34], 806 
[35], 807 [36] and 820 [16], defined the definition of the 
manufacturer. This definition of a manufacturer includes 
anyone who: 
- Develops specification; 
- Designs; 
- Labels; 
- Creates a software system or application for a regulated 
medical device. 
With the release of the FDA final guidance on mobile 
medical applications, the ambiguity surrounding who is 
defined as a manufacturer has now been removed. Certainty 
has also been provided in that distributors of MMAs do not 
meet the definition of being manufacturers and as such avoid 
regulatory scrutiny i.e. the Apple App Store and Google Play 




CATEGORIES OF MMAS BY THE FDA [4] 
Applications 
Functionality Example Consideration 







Display of medical 
images X-Rays and 
MRI, graphic data 
such as EEG 
waveforms, bedside 
monitors 
High Risk – good 
resolution of the 
screen is extremely 
important in certain 
cases like X-Ray/MRI 
as lower resolution 
may affect clinical 
decision negatively 
Applications that 
convert a mobile 








transducers to make 
stethoscopes, 
spirometers 
High Risk – readings 
may directly affect 
the clinical decisions 
therefore the apps 





treatment options on 
the basis of patient 
specific input 




Medium Risk – The 
geographic region is 
very important. If a 
drug is not available 
over the counter and 
patients need a 
prescription then its 
low risk. 
Apps for general 
health applications & 
education purposes 
BMI Calculators, 




Low Risk – 
Marketing claims are 
critical for products to 
be placed in general 
health benefits 
category, which is 
very low risk, most 
health applications for 
mass public 
consumption are 
likely to fall under 
this category 
C. Mobile Medical Application Safety Classification 
As with all software or devices used in connection with 
patient care, once a mobile application meets the definition of 
being a mobile medical application it must be classified as 
Class I, Class II or Class III. As discussed previously, all 
mobile medical applications initially are classified as Class I 
devices if they meet the definition of being an MDDS, or as a 
Class III device until reclassified by the FDA.  
The FDA as part of its guidance has also covered guidance as 
to MMAs, which it intends to exercise enforcement 
discretion2. Examples include apps which: 
- Help patients self-manage their disease of conditions; 
- Provide patients with simple tools to organize and track 
their health information; 
- Provide easy access to information related to patients’ 
health; 
- Automate simple tasks for health care providers i.e. 
MDDS. 
IV. DEVELOPING MOBILE MEDICAL APPLICATIONS 
A. Developing Regulatory Compliant Software 
Despite not dictating a Software Development Life Cycle 
(SDLC) to follow, medical device software development 
organizations typically follow the V-Model [38]. It was first 
presented in 1991 at the NCOSE symposium [39] and is a 
variation on a SDLC which Royce presented which later 
became known as the Waterfall Model [40]. The V-Model 
identifies that there are different types of testing such as 
modular testing and integration testing [41]. The V-Model 
shows the relationship between the two sides of the 
development process. This relationship is used to determine 
whether the stage has been completed successfully. If a 
problem occurs during the verification or validation of any one 
stage, then the opposite stage on the “V” must be revisited and 
if necessary, reiterated [42]. Essentially, the testing of a 
product is planned in parallel with the corresponding phase of 
development. This method of developing software eases the 
process of achieving traceability. The FDA mandates that 
traceability be an integral part of a development process [43]. 
Therefore, the V-Model is perceived to be the “best fit” with 
the regulatory requirements. While it may be the best fit, in 
practice the V-Model presents the same problems that are 
associated with utilizing any sequential plan driven SDLC. 
Royce, who presented the Waterfall model, stated that there 
are inherent problems associated with following a sequential 
lifecycle [40]. For example, as requirements are fixed at such 
an early stage, it can be very difficult to introduce a change in 
requirements once the project is underway. Furthermore, it can 
be very difficult to capture all of the requirements at such an 
early stage of a project [44]. In addition to this, any changes 
introduced once a project is underway can create cost and 
budget overruns [45]. 
B. Agile Software Development 
Recognizing the inadequacies associated with plan-driven 
approaches, a shift has occurred toward a more flexible or 
agile approach to software development. Agile software 
development was first formalized in 2001 and since then has 
 
2 The term enforcement discretion means that even if a mobile application 
may meet the definition of being a medical device, the FDA can choose not to 
enforce our requirements because we determined that the risk to patients is 
low – Bakul Patel, Senior Policy Advisor to the center director – CDRH and 
FDA [37]  
  
gained greater acceptance in the software development 
industry. This is evident in a large scale survey of software 
development organizations, conducted in 2013, which 
identified that 88% organizations stated that they were 
following an agile approach [46]. This is an increase from 
84% in 2012 [47] and 80% in 2011 [48].  
The principles of agile software development originate from 
the “Agile Manifesto” [49]. In February 2001, a meeting was 
held at The Lodge at Snowbird ski resort in Utah. At this 
meeting, 17 people met including Kent Beck, Alistair 
Cockburn, and Robert C. Martin, all very experienced in the 
field of software engineering, to discuss software development 
methodologies. As a result of this meeting, the agile software 
development alliance emerged. The agile alliance determined 
the priorities of a development project, as shown in Table III: 
 
TABLE III 
AGILE SOFTWARE DEVELOPMENT VALUES 
Individuals and interactions over processes and tools; 
Working software over comprehensive documentation; 
Customer collaboration over contract negotiation; 
Responding to change over following a plan. 
 
In essence, agile principles place a greater importance on 
the human component of a development project, rather than on 
utilising a rigid plan i.e. people over processes [50].  
Cursory reading of these values would appear to suggest 
that agile methods are contradictory to regulatory 
requirements as none of the regulatory deliverables such as 
documentation are produced. Further examination of the agile 
values identified that the statements on the left are deemed of 
greater importance than those on the right in an agile project, 
however they do not replace the items on the right. For 
example, as identified by Robert Martin [50], one of the 
authors of the Agile Manifesto states “Produce no document 
unless it’s immediate and significant” demonstrating that as 
long as there is value to be obtained by the items on the right, 
they should still be produced. 
Regulatory requirements have been put in place to ensure 
that software produced for use in connection with patient care 
is of the highest quality. Furthermore, quality is one of the 
main aims of the agile software development. In agile, 
software development, planning, requirements definition, 
design, testing and validation are all performed, however, they 
are performed over several increments which are designed to 
give feedback early in a software project. This approach 
allows for greater clarity and control of a software 
development process, more so than traditional plan driven 
approaches such as the Waterfall of V-Model. This feedback 
loop can be modified to incorporate risk management, human 
factors, and verification and validation that meet the FDA’s 
quality system regulations. 
Another example as to how agile methods may be 
incompatible in the medical device domain is the difficulty 
associated with incremental development. In non-regulated 
software development adopting agile approaches, the software 
is developed partially, examined and if necessary, reiterated. 
This examination can come in the form of alpha or beta testing 
or possibly release to end users with the subsequent elements 
being updated based on the feedback obtained. In the medical 
domain and other safety-critical domains, it is not possible to 
release software into a live environment without adequate 
testing and regulatory approval. 
1) AAMI TIR45:2012 
In October 2012, the Association for the Advancement of 
Medical Instrumentation (AAMI) released a Technical 
Information Report (TIR) known as AAMI TIR 45:2012 
Guidance on the use of agile practices in the development of 
medical device software [51]. The committee that developed 
the TIR consisted of industry experts and FDA staff. AAMI 
recognized the shift in the generic software development 
industry towards more agile practices and the evidence 
presented from successful adoption of agile practices in 
medical device software development organizations. However, 
they identified that the available information with regards to 
the adoption of agile practices when developing medical 
device software was hard to understand and the objective of 
the TIR is to provide clear guidance of which practices of 
agile software development are suited to the development of 
medical device software. The TIR also provides 
recommendations for complying with international standards 
and FDA guidance documents when using agile practices to 
develop medical device software. 
The TIR focuses on a number of areas in which agile 
software development practices are suited when developing 
medical device software. These areas include: 
• Planning; 
• Team Structure and Collaboration; 
• Product Definition and Requirements Documentation; 
• Software Architecture; 
• Detailed Design; 
• Implementation and Unit Verification; 
• Integration and Integration Testing; 
• Software System Testing; 
• Software Release; 
• Configuration Management and Change Management; 
• Corrective and Preventative Action. 
The TIR successfully maps practices performed as part of 
agile software development techniques to each of these stages 
of development. Whilst the TIR can be seen as useful when 
developing medical device software, two issues can 
potentially arise. Firstly, the TIR maps agile practices to IEC 
62304; IEC 62304 only provides guidance for the 
development of the software portion of a medical device 
system and therefore, it could be difficult to apply the TIR to 
the development of standalone software. Secondly, the TIR 
only provides high-level guidance as to specific agile practices 
that can be used when developing medical device software. 
Many more agile practices exist which could potentially be 
used in the development of medical device software, but are 
not included in the TIR. This TIR is not a hands-on approach 
on agile methods. It provides a good discussion on what can 
be done or what can’t be done with agile methods, and it 
  
serves to reassure people who are skeptical about agile 
methods. Additionally, while this TIR may not be 
comprehensive in its approach, it does serve as evidence of the 
changing attitude of the FDA with regards the use of agile 
software development approaches when developing regulatory 
compliant software. 
C. Can Agile approaches be used in practice? 
Rasmussen, et al. [11] detailed the successful 
implementation of agile practices within Abbott Diagnostics, 
the organization recognized the need to move away from a 
plan-driven approach. In this implementation, Abbott 
completed two projects side-by-side, one in accordance with 
agile methods and the other in accordance with a plan-driven 
approach. While both projects were not the same size, the 
organization identified that the project completed in 
accordance with agile methods made a cost saving of between 
35% and 50% when compared to the plan-driven project. 
Rottier and Rodrigues [12] detailed the implementation of 
an agile approach within Cochlear. As with Abbott 
Diagnostics, Cochlear wished to streamline their development 
process by moving away from a plan-driven approach to a 
more agile one. However, they quickly identified that it was 
not possible to wholly adopt a single agile method, such as 
Scrum or XP on its own, as no single agile method provides 
sufficient guidance of each of the stages, which are necessary 
when developing medical device software. This supports the 
findings of Vogel [52] and Turk, et al. [53], who also 
identified that no single agile method is sufficiently 
comprehensive for use when developing medical/safety 
critical software. Within Cochlear, it was identified that 
combining an agile method such as Scrum with a plan-driven 
SDLC such as the V-Model, sufficient guidance for the 
development of regulatory compliant software is provided.  
Spence [54] discussed the implementation of Scrum within 
Medtronic. Spence identified that it is not practical to follow a 
rigid plan-driven approach when developing medical device 
software, as it is not possible to fully complete one stage of 
development before moving on to the next, whilst ruling out 
the need to revisit a stage. The research conducted by Spence 
is related more to the organizational challenges associated 
with implementing agile in a medical device software 
development organization. Further to this, Weyrauch [55] 
published research on the adoption of agile practices within 
Medtronic. He builds further on the information presented by 
Spence, however, the detail he presented remained closer to 
the organizational impact and accommodation of agile 
methods, rather than the impact agile practices had on a 
software development project. 
Weiguo and Xiaomin [56] presented a SDLC, which 
incorporates practices with a plan-driven approach and was 
implemented on a medical device software development 
project. Unfortunately, the information presented by the 
authors is very sparse and they do not provide enough 
guidance as to how their tailored SDLC was implemented 
should an organization wish to adopt their SDLC. However, 
they do outline that rather than wholly adopting a single agile 
method, they retained the V-Model/plan-driven approach to 
produce the necessary regulatory deliverables. 
While the detail included as part of each of these 
implementations is sparse, commonalities can be identified. 
Each of the organizations initially examined the possibility of 
wholly adopting a single agile method such as Scrum or XP. 
They soon realized this was not possible and as such they 
integrated selected agile practices with their traditional plan-
driven approach. Furthermore, the selected practices typically 
originated from either the Scrum or XP approaches.   
V. CONCLUSIONS 
The FDA does not regulate specific forms of medical 
devices; rather they regulate all devices that are intended for 
use in connection with patient care. While the regulations 
attempt to provide clear information to device manufacturers, 
ambiguity can arise when they try to apply the regulations to 
specific medical device sectors such as medical device 
software. As a result, the FDA has released a number of 
guidance documents to help medical device software 
manufacturers to navigate the regulatory process. The latest 
guidance document released by the FDA is intended for MMA 
manufacturers and FDA staff. This document details when a 
mobile application is deemed a mobile medical application 
and if so, the necessary steps, which must be taken in order to 
achieve regulatory approval. These steps increase the 
overhead associated with developing such apps and as such, 
there is the potential to deter mobile medical application 
manufacturers from entering the market, which could 
ultimately lead to a reduction in competition and 
advancements. This paper discussed how by adopting agile 
software development techniques MMA manufacturers could 
continue to develop apps which meet regulatory approval, 
whilst not sacrificing the approach which they may be 
accustomed i.e. producing little documentation and fast 
development cycles. To achieve this, MMA manufacturers are 
advised to follow a hybrid software development approach. 
This hybrid approach would involve following the V-Model. 
This will assist in producing regulatory deliverables along 
with adopting agile practices, which will assist in promoting 
development and innovation. 
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